Five-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a…
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially…